InnoCare Pharma, Eli Lilly sign $3B collaboration deal

Eli Lilly: Eli Lilly is a major global pharmaceutical company engaged in the research, development, and commercialization of medicines across therapeutic areas including oncology and immunology. The company has been actively expanding its pipeline through external collaborations, particularly in China. This agreement positions Lilly to access InnoCare's discovery capabilities for potential new treatments. InnoCare Pharma: InnoCare Pharma is a Beijing-based biopharmaceutical company focused on discovering, developing, and commercializing innovative drugs for cancer and autoimmune diseases. It maintains a proprietary drug discovery platform and has advanced multiple candidates through clinical trials in recent months. In this news, InnoCare is entering a multi-target research collaboration and licensing deal with Eli Lilly to advance up to five new compounds. China Biotech Partnerships: Eli Lilly has pursued multiple recent collaborations with Chinese biopharmaceutical firms to source innovative drug candidates and accelerate development. Autoimmune and Oncology Focus: Chinese biotechs specializing in cancer and autoimmune therapies continue to attract international partners seeking to expand their pipelines in high-unmet-need areas.